Skip to Content

.

.

Full publication lists

ORCID | Google Scholar | ResearchGate



Publication highlights

Elz AS, Trevaskis NL, Porter CJH, Bowen JM, Prestidge CA. Smart design approaches for orally administered lipophilic prodrugs to promote lymphatic transport. J Control Release, Dec 9:S0168-3659(21)00654-4 (2021)

Gracia G, Cao E, Kochappan R, Porter CJH, Johnston A, Trevaskis NL. Association of a vaccine adjuvant with endogenous HDL increases lymph uptake and dendritic cell activation. Eur J Pharm Biopharm, Sep 24:S0939-6411(21)00236-8 (2021)

Cao E, Watt MJ, Nowell CJ, Quach T, Simpson JS, De Melo Ferreira V, Agarwal S, Chu H, Srivastava A, Anderson D, Gracia G, Lam A, Segal G, Hong J, Hu L, Phang KL, Escott ABJ, Windsor JA, Phillips ARJ, Creek DJ, Harvey NL, Porter CJH, Trevaskis NL. Mesenteric lymphatic dysfunction promotes insulin resistance and represents a potential treatment target in obesity. Nat Metab, 3(9), 1175-1188 (2021)

Han S, Mei L, Quach T, Porter C, Trevaskis N. Lipophilic Conjugates of Drugs: A Tool to Improve Drug Pharmacokinetic and Therapeutic Profiles. Pharm Res, 38(9), 1497-1518 (2021)

Trevaskis NL. Intestinal lymphatic dysfunction: a new pathway mediating gut-kidney crosstalk in kidney disease. Kidney Int, 100(3), 511-513 (2021)

Kochappan R, Cao E, Han S, Hu L, Quach T, Senyschyn D, Ferreira VI, Lee G, Leong N, Sharma G, Lim SF, Nowell CJ, Chen Z, von Andrian UH, Bonner D, Mintern JD, Simpson JS, Trevaskis NL, Porter CJH. Targeted delivery of mycophenolic acid to the mesenteric lymph node using a triglyceride mimetic prodrug approach enhances gut-specific immunomodulation in mice. J Control Release, 332, 636-651 (2021)

Lee G, Han S, Lu Z, Hong J, Phillips ARJ, Windsor JA, Porter CJH, Trevaskis NL. Intestinal delivery in a long-chain fatty acid formulation enables lymphatic transport and systemic exposure of orlistat. Int J Pharm, 596, 120247 (2021)

Han S, Quach T, Hu L, Lim SF, Gracia G, Trevaskis NL, Simpson JS, Porter CJH. The Impact of Conjugation Position and Linker Chemistry on the Lymphatic Transport of a Series of Glyceride and Phospholipid Mimetic Prodrugs. J Pharm Sci, 110(1), 489-499 (2021)

Vasanthakumar, A., Chisanga, D., Blume, J., Gloury, R., Britt, K., Henstridge, D.C., Zhan, Y., Torres, S.V., Liene, S., Collins, N., Cao, E., Sidwell, T., Li, C., Spallanzani, R.G., Liao, Y., Beavis, P.A., Gebhardt, T., Trevaskis, N., Nutt, S.L., Zajac, J.D., Davey, R.A., Febbraio, M.A., Mathis, D., Shi, W. & Kallies, A. Sex-specific adipose tissue imprinting of regulatory T cells. Nature 579, 581-585 (2020).

Trevaskis, N.L., Lee, G., Escott, A., Phang, K.L., Hong, J., Cao, E., Katneni, K., Charman, S.A., Han, S., Charman, W.N., Phillips, A.R.J., Windsor, J.A. & Porter, C.J.H. Intestinal Lymph Flow, and Lipid and Drug Transport Scale Allometrically From Pre-clinical Species to Humans. Front Physiol 11, 458 (2020).

Porter, C.J.H. & Trevaskis, N.L. Targeting immune cells within lymph nodes. Nature Nanotechnology 15, 423-425 (2020).

Gracia, G., Cao, E., Johnston, A.P.R., Porter, C.J.H. & Trevaskis, N.L. Organ-specific lymphatics play distinct roles in regulating HDL trafficking and composition. Am J Physiol Gastrointest Liver Physiol 318, G725-G735 (2020). *Editors choice

Gracia, G., Cao, E., Feeney, O.M., Johnston, A.P.R., Porter, C.J.H. & Trevaskis, N.L. High-Density Lipoprotein Composition Influences Lymphatic Transport after Subcutaneous Administration. Mol Pharm 17, 2938-2951 (2020).

Lee, G., Han, S., Inocencio, I., Cao, E., Hong, J., Phillips, A.R.J., Windsor, J.A., Porter, C.J.H. & Trevaskis, N.L. Lymphatic Uptake of Liposomes after Intraperitoneal Administration Primarily Occurs via the Diaphragmatic Lymphatics and is Dependent on Liposome Surface Properties. Mol Pharm 16, 4987-4999 (2019).

Cao, E., Lindgren, A., Martinsson, S., Hu, L., Lindfors, L., Sigfridsson, K., Skantze, U., Michaelsson, E., Trevaskis, N.L. & Porter, C.J.H. Promoting intestinal lymphatic transport targets a liver-X receptor (LXR) agonist (WAY-252,623) to lymphocytes and enhances immunomodulation. J Control Release 296, 29-39 (2019).

Yadav, P., McLeod, V.M., Nowell, C.J., Selby, L.I., Johnston, A.P.R., Kaminskas, L.M. & Trevaskis, N.L. Distribution of therapeutic proteins into thoracic lymph after intravenous administration is protein size-dependent and primarily occurs within the liver and mesentery. J Control Release 272, 17-28 (2018). * Cover paper with editorial

Verma, P., Prajapati, S.K., Yadav, R., Senyschyn, D., Shea, P.R. & Trevaskis, N.L. Single Intravenous Dose of Novel Flurbiprofen-Loaded Proniosome Formulations Provides Prolonged Systemic Exposure and Anti-inflammatory Effect. Mol Pharm 13, 3688-3699 (2016). *ACS Editors choice

Hu, L., Quach, T., Han, S., Lim, S.F., Yadav, P., Senyschyn, D., Trevaskis, N.L., Simpson, J.S. & Porter, C.J. Glyceride-Mimetic Prodrugs Incorporating Self-Immolative Spacers Promote Lymphatic Transport, Avoid First-Pass Metabolism, and Enhance Oral Bioavailability. Angew Chem Int Ed Engl 55, 13700-13705 (2016). *Frontiespiece

Han, S., Quach, T., Hu, L., Wahab, A., Charman, W.N., Stella, V.J., Trevaskis, N.L., Simpson, J.S. & Porter, C.J. Targeted delivery of a model immunomodulator to the lymphatic system: comparison of alkyl ester versus triglyceride mimetic lipid prodrug strategies. J Control Release 177, 1-10 (2014). * Cover paper with editorial

Key review papers

Abdallah, M., Mullertz, O.O., Styles, I.K., Morsdorf, A., Quinn, J.F., Whittaker, M.R. & Trevaskis, N.L. Lymphatic targeting by albumin-hitchhiking: Applications and optimisation. J Control Release 327, 117-128 (2020).

Feeney, O.M., Gracia, G., Brundel, D., Trevaskis, N.L., Cao, E., Kaminskas, L.M. & Porter, C.J.H. Lymph-directed immunotherapy – harnessing endogenous lymphatic immune  trafficking pathways for enhanced therapeutic outcomes. Adv Drug Deliv Rev In press(2020).

Sarfarazi, A., Lee, G., Mirjalili, S.A., Phillips, A.R.J., Windsor, J.A. & Trevaskis, N.L. Therapeutic delivery to the peritoneal lymphatics: Current understanding, potential treatment benefits and future prospects. Int J Pharm 567, 118456 (2019).

Koziolek, M., Alcaro, S., Augustijns, P., Basit, A.W., Grimm, M., Hens, B., Hoad, C.L., Jedamzik, P., Madla, C.M., Maliepaard, M., Marciani, L., Maruca, A., Parrott, N., Pavek, P., Porter, C.J.H., Reppas, C., van Riet-Nales, D., Rubbens, J., Statelova, M., Trevaskis, N.L., Valentova, K., Vertzoni, M., Cepo, D.V. & Corsetti, M. The mechanisms of pharmacokinetic food-drug interactions - A perspective from the UNGAP group. Eur J Pharm Sci 134, 31-59 (2019)

Feeney, O.M., Crum, M.F., McEvoy, C.L., Trevaskis, N.L., Williams, H.D., Pouton, C.W., Charman, W.N., Bergstrom, C.A.S. & Porter, C.J.H. 50years of oral lipid-based formulations: Provenance, progress and future perspectives. Adv Drug Deliv Rev 101, 167-194 (2016)

Trevaskis, N.L., Kaminskas, L.M. & Porter, C.J. From sewer to saviour - targeting the lymphatic system to promote drug exposure and activity. Nat Rev Drug Discov 14, 781-803 (2015). *cover paper

Trevaskis, N.L., Hu, L., Caliph, S.M., Han, S. & Porter, C.J. The mesenteric lymph duct cannulated rat model: application to the assessment of intestinal lymphatic drug transport. J Vis Exp (2015)

Williams, H.D., Trevaskis, N.L., Charman, S.A., Shanker, R.M., Charman, W.N., Pouton, C.W. & Porter, C.J. Strategies to address low drug solubility in discovery and development. Pharmacol Rev 65, 315-499 (2013)

Trevaskis, N.L., Charman, W.N. & Porter, C.J. Lipid-based delivery systems and intestinal lymphatic drug transport: a mechanistic update. Adv Drug Deliv Rev 60, 702-716 (2008).

Porter, C.J., Trevaskis, N.L. & Charman, W.N. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov 6, 231-248 (2007).

Patents

Trevaskis, N.L., Porter, C.J.H., Lee, G., Han, S., Windsor, J.A., Philllips, A.R.J., Hong, J. Lymph-targeting oral formulation of orlistat; Provisional patent, Monash ref: 2019-119-01; DCC ref: 35548449/MJC/GDB, Filing Date 26/10/20

Trevaskis, N.L., Porter, C.J.H., Quach, T., Han, S., Hu, L, Cao, E. Methods and Compounds for the Treatment of Metabolic Disease. PCT/AU2020/050997, Filing Date 21/9/2020

Han, S., Hu, L, Porter, C.J.H., Quach, T., Trevaskis, N.L., Zhou, X. Lipid prodrugs of cannabinoids and uses thereof. Provisional U.S. patent application. Application No. 63/049,474, Filing date: July 8, 2020

Trevaskis, N.L., Porter, C.J.H., Quach, T., Han, S., Hu, L, Cao, E. Methods and Compounds for the Treatment of Metabolic Disease. US Provisional 62/902,600, Filing Date 19/9/2019

Bonner, D.K., Karanam, K., Simpson , J., Bolen J., Han, S., Porter, C.J.H., Quach, T., Trevaskis, N.L., Leong, N., Sharma, G., Zheng, D., McInerney, M. Lipid prodrugs of glucocorticoids and uses thereof. Provisional US 62/811,931, Filing Date: 02/28/2019; PCT/US2020/020387, Filing date 02/28/2020

Bonner, D.K., Karanam, K., Simpson, J., Bolen J., Han, S., Porter, C.J.H., Quach, T., Trevaskis, N.L., Leong, N., Sharma, G., Zheng, D., McInerney, M. Lipid  prodrugs of Btk Inhibitors and uses thereof. Provisional US 62/812,071, Filing Date: 02/28/2019, PCT/US2020/020433, Filing date 02/28/2020

Bonner , D.K., Karanam, K., Simpson, J., Bolen J., Han, S., Porter, C.J.H., Quach, T., Trevaskis, N.L Leong, N., Sharma, G., Zheng, D., McInerney, M. Lipid  prodrugs of Jak Inhibitors and uses thereof, Provisional, US 62/812,099, Filing Date: 02/28/2019, PCT/US2020/020398, Filing date 02/28/2020

Bonner, D.K., Karanam, K., Simpson, J. Han, S., Hu., L. Porter, C.J.H., Quach, T., Trevaskis, N.L. Lipid prodrugs of pregnane neurosteroids and uses thereof, Provisional (1) US 62/713,972, Filing Date: 08/02/2018, Provisional (2) US 62/789,352, Filing Date: 01/07/2019; PCT/US2019/044877, Filing Date: 08/02/2019

Bonner, D.K., Karanam, K., Mutumba, J.T., Shyam, R.R., Simpson, J., Han, S., Hu, L., Porter, C.J.H., Quach, T., Trevaskis, N.L. LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS, US Provisional 62/714,029, Filing date: 08/02/2018, PCT/US2018/48642, Filing Date: 08/29/2018

Bonner, D.K., Han, S., Hu, L., Karanam, K., Porter, C.J.H., Quach, T., Shyam, R.R., Simpson, J., Trevaskis, N.L. Lipid prodrugs of mycophenolic acid and uses thereof, Provisional (1) US 62/607,749, Filing Date: 12/19/2017, Provisional (2) US 62/768,583, Filing Date: 11/16/2018 Provisional (3), US 62/724,274, Filing Date: 08/29/2018, PCT/US2018/66585, Filing date 12/19/2018

Bonner, D.K., Han, S., Hu, L., Karanam, K., Porter, C.J.H., Quach, T., Shyam, R.R., Simpson, J., Trevaskis, N.L Lipid prodrugs of rapamycin and its analogues and uses thereof, Provisional (1) US 62/607,700, Filing Date: 12/19/2017, US 62/724,440, Provisional (2), Filing Date: 08-29-2018, PCT/US2018/66580, Filing Date: 12/19/2018

Porter , C.J.H., Simpson, J., Trevaskis, N.L., Quach, T., Han, S., Hu, L. Lymph directing prodrugs. Provisional AU2015903661, Filing Date 8 Sept 2015 PCT/AU2016/050845, Filing Date 8 Sept 2016

Porter , C.J.H., Simpson, J., Trevaskis, N.L., Quach, T., Han, S., Hu, L. Lymph Directing prodrugs. Provisional AU2014903148, Filing date 12 August 2014, PCT/AU2015/050460, Filing Date 12 Aug 2015